Compare SGLD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGLD | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 67.0M |
| IPO Year | 2009 | 2017 |
| Metric | SGLD | SPRO |
|---|---|---|
| Price | $3.35 | $1.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 40.8K | ★ 472.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $3.26 | $1.08 |
| 52 Week High | $5.45 | $3.08 |
| Indicator | SGLD | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 42.98 |
| Support Level | $3.26 | $1.10 |
| Resistance Level | $3.82 | $1.28 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 16.98 | 10.00 |
Scorpio Gold Corp is a company that is engaged in mineral exploitation, exploration, and development in the United States. It holds an interest in the Mineral Ridge gold project, which is located in the northwest of the town of Silver Peak and west of Tonopah in Esmeralda County, Nevada. Its other project includes the Goldwedge property, which is located north-northeast of the town of Tonopah within the Manhattan Mining District of south-central Nevada.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.